StonvexLoading…
StonvexStonvexStonvexCore line items from PATH's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2026 (Est.) Expected 2026-05-28 | Annual 2026 2026-01-31 | Q4 2025 2025-10-31 | Q3 2025 2025-07-31 | Q2 2025 2025-04-30 |
|---|---|---|---|---|---|
Revenue | $405.77M | $1.61B | $1.13B | $718.35M | $356.62M |
Operating Income | Not available | $56.76M | $-23.53M | $-36.60M | $-16.41M |
Net Income | Not available | $282.33M | $177.87M | $1.58M | $-22.55M |
EPS (Diluted) | $0.16 | $0.52 | $0.33 | $-0.04 | $-0.04 |
Total Assets | Not available | $3.18B | $2.90B | $2.59B | $2.64B |
Total Liabilities | Not available | $1.10B | $971.36M | $926.61M | $945.98M |
Cash & Equivalents | Not available | $871.16M | $743.66M | $628.62M | $700.64M |
Free Cash Flow OCF − CapEx | Not available | $352.16M | $172.86M | $147.76M | $106.17M |
Shares Outstanding | Not available | 544.86M | 544.72M | 542.21M | 548.45M |